Fannie Mae, Freddie Mac shares tumble after conservatorship comments
Benjamin Regina M., a director at Doximity , Inc. (NYSE:DOCS), recently sold a significant portion of the company’s Class A Common Stock. According to a recent SEC filing, Regina sold shares worth approximately $3.05 million. The transactions, which took place on February 11, 2025, involved selling a total of 39,000 shares at prices ranging from $74.9983 to $79.6714 per share. The sale comes as Doximity’s stock has shown remarkable strength, gaining 159% over the past year and maintaining an impressive 90% gross profit margin. According to InvestingPro analysis, the company currently appears overvalued at its current market cap of $14.34 billion.
Prior to these sales, Regina acquired 40,000 shares through an option exercise, converting Class B Common Stock into Class A Common Stock. Post-transaction, Regina holds 16,618 shares of Class A Common Stock directly.
These transactions are part of routine financial activities conducted by company insiders and are often monitored closely by investors for insights into the company’s performance and insider sentiment.
In other recent news, Doximity, a professional network for physicians, has been the subject of numerous analyst upgrades and price target revisions following its impressive financial performance. Jefferies analyst Glen Santangelo raised the price target for Doximity to $88 from $64, maintaining a Buy recommendation. The analyst highlighted the company’s robust growth and profitability, with a growth rate exceeding 25% and an EBITDA margin above 60%.
Mizuho (NYSE:MFG) Securities analyst Steven Valiquette also increased the price target for Doximity to $65 from $55, following the company’s reported fiscal third-quarter revenue of $168 million, a 25% year-over-year increase. Piper Sandler analyst Sean Wieland upgraded shares of Doximity from Neutral to Overweight, significantly raising the price target to $78 from the previous $31, citing the company’s substantial revenue and adjusted EBITDA beat.
KeyBanc Capital Markets reiterated its Overweight rating and $65.00 price target on Doximity, following the company’s financial performance, with revenues increasing by 25% year-over-year and adjusted EBITDA margins reaching 60.5%. Lastly, Needham maintained a Buy rating on Doximity and increased its price target to $82.00 from the previous $65.00, following an exceptional third quarter. These are all recent developments in the company’s financial performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.